Leap Therapeutics

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of -9.09% and -3.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Leap Therapeutics, Inc. (LPTX) Reports Q1 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass., May 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2021.

Leap Therapeutics Reports First Quarter 2021 Financial Results

Leap Therapeutics and Flagship Biosciences Develop Image Analysis RNAscope Assay for Prospective Trial Enrollment

Leap Therapeutics, Inc. (LPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Leap Therapeutics, Inc. (LPTX) Report Negative Q1 Earnings? What You Should Know

Charles & Colvard

Kazia Therapeutics

Benjamin Graham, the pioneer of value investing, proposed to look for stocks that have a current ratio of more than 2 and more working capital than long-term debt.

A Trio of Stocks With Solid Balance Sheets for the Value Investor

The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased by over 2.5% pre-market. This is why it happened.

LPTX Stock: Over 2.5% Increase Pre-Market Explanation

Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment

CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the completion of enrollment for the first-line patient cohort in the DisTinGuish study, a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.

Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics Inc (NASDAQ: LPTX) has announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 as a monotherapy and in combination with paclitaxel in patients with advanced gynecological malignancies. Leap presented the data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer.

Leap Therapeutics Stock Is Trading Higher After Encouraging DKN-01 Data At Gynecologic Oncology Meet

The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased by over 25% pre-market. This is why it happened.

LPTX Stock Price Increases Over 25% Pre-Market: Why It Happened

CAMBRIDGE, Mass., March 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 as a monotherapy and in combination with paclitaxel in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer, being held as a virtual meeting from March 19-25, 2021.

Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer

Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of -12.50% and -6.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Leap Therapeutics, Inc. (LPTX) Reports Q4 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020.

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at...

Leap Therapeutics to Present at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the publication in Molecular Cancer Research of preclinical results from studies of human and...

Leap Therapeutics Announces Publication of DKN-01 Mechanism of Action Data in Molecular Cancer Research

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat...

Leap Therapeutics to Participate at Piper Sandler 32nd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at...

Leap Therapeutics to Present at Stifel 2020 Healthcare Conference

CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 in patients with...

Leap Therapeutics Presents DKN-01 Monotherapy Data at AACR Virtual Special Endometrial Cancer Conference

Cia Brasileira de Distribuicao

Cisco Systems

Chevron

Honeywell

Intel

JPMorgan Chase & Co

UnitedHealth Group

Verizon

Walmart

cbdMD Inc

Two new breakout stocks for Week 46 with better than 10% short-term upside potential. This past week three out of four stocks gained more than 10% closing with gains to Friday with AVNS +8.54%, IMVT +14.96%, YY +10.85% with top average portfolio gains of 11.14%.

Week 46 MDA Breakout Forecast - November: Short-Term Picks To Give You An Edge

CAMBRIDGE, Mass., Sept. 24, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DKN-01...

Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

CAMBRIDGE, Mass. and BEIJING, Sept. 21, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and BeiGene, Ltd., (Nasdaq:BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on...

Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.

Leap Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

CAMBRIDGE, Mass., Aug. 13, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.

Leap Therapeutics Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., June 25, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an additional 3,375,000 shares of common stock pursuant to the full exercise of...

Leap Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Leap Therapeutics (LPTX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Leap Therapeutics (LPTX) Soars: Stock Adds 8.3% in Session

News for Leap Therapeutics Stock (LPTX)